The cannabis industry is entering a clear phase of consolidation after an early period of capital frenzy and a sharp retreat in share prices. Weaker players are exiting, while stronger companies are expanding through acquisitions. With individual stock volatility rising and deal outcomes uncertain, building exposure through cannabis-themed ETFs is becoming an increasingly attractive way to position for the sector.
Investor enthusiasm was extremely high when cannabis stocks first began trading. A gold rush mentality led to a flood of new listings. Although the overall industry has continued to grow, most individual companies have failed to live up to lofty early expectations. Cannabis shares now trade well below their early highs, and a shakeout is underway. Acquisitions have become a central theme.
Curaleaf recently launched an unsolicited bid for Aurora Cannabis, offering $4 per share, a 45% premium to Aurora’s 30-day average price. The consideration includes $0.75 per share in cash and 0.3463 of a Curaleaf share per Aurora share, with a cap of $5 per share. Aurora said it will consider the offer, though the tone of its statement suggested it is unlikely to accept the current terms.
Over the long term, the biggest winners in the consolidation wave are likely to be the consolidators themselves. Companies that expand through acquisitions can gain market share and improve fundamentals over time. Notably, Aurora is also participating in consolidation, having recently acquired Safari Flower to strengthen its medical cannabis business.
During industry consolidation, individual stocks carry both the potential for short-term takeover gains and the risk of failed deals or disappointing operations. Betting on a single name involves considerable uncertainty. The long-term growth outlook for cannabis remains strong. Fortune Business Insights projects the global market will reach $1.4 trillion by 2034, with a compound annual growth rate of 34%. Yet which individual companies will emerge as winners is far from certain.
Cannabis ETFs reduce concentration risk by spreading capital across a basket of stocks. For investors seeking exposure to industry growth without taking on single-company acquisition or operating risk, ETFs provide a practical route.
Five major cannabis ETFs stand out.
The AdvisorShares Pure U.S. Cannabis ETF (MSOS) is the largest marijuana ETF, with roughly $926.4 million in assets and a 0.78% expense ratio as of May 7, 2026. It focuses exclusively on the U.S. cannabis market and holds swaps tied to U.S. operators including Curaleaf, Trulieve, Green Thumb Industries, Verano Holdings, Glass House Brands, and Cresco Labs.
The Amplify Alternative Harvest ETF (MJ) has about $112 million in assets and a 0.75% expense ratio. It was the first U.S. ETF to target the global cannabis market. Its top holdings include Tilray Brands, Cronos Group, Canopy Growth, SNDL, and Village Farms International, which together account for about 40% of total assets. Around 50% of the fund is invested in its sister fund, Amplify Seymour Cannabis ETF. With a significant weighting in Canadian producers, the fund may face headwinds while marijuana remains illegal at the U.S. federal level.
The Global X Marijuana Life Sciences Index ETF (HMMJ) has CAD$43.7 million in assets and a 1.00% expense ratio. It is not listed on a major U.S. exchange, but U.S. investors can buy it over the counter. Top five holdings include Jazz Pharmaceuticals, Cronos Group, Innovative Industrial Properties, Tilray Brands, and Canopy Growth, making up about 51% of total assets.
The AdvisorShares Pure Cannabis ETF (YOLO) has about $33.7 million in assets and a 0.51% expense ratio. Unlike MSOS, it focuses on the global cannabis market. More than 21% of its assets are invested in MSOS. Top individual holdings include Curaleaf, Trulieve, Village Farms International, High Tide, and Cronos Group, representing over 50% of the fund.
The Amplify Seymour Cannabis ETF (CNBS) has about $76.5 million in assets and a 0.76% expense ratio. Managed by well-known cannabis investor Tim Seymour, the fund held 33 stocks. Its largest positions include swaps tied to Trulieve, Curaleaf, Green Thumb Industries, Glass House Brands, and Verano Holdings, as well as Curaleaf shares, together accounting for roughly 67% of assets. U.S. multi-state operators make up a large share of the portfolio.
Overall, the cannabis industry is transitioning from disorderly expansion toward greater concentration. Rising M&A activity will reshape the competitive landscape, and the ultimate winners are likely to be companies with the ability to integrate. For ordinary investors, holding a diversified basket of companies through ETFs during this consolidation phase can reduce single-stock selection risk while maintaining exposure to the sector’s long-term growth.
